nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—EGFR—dilated cardiomyopathy	0.71	1	CbGaD
Afatinib—ABCB1—Lisinopril—dilated cardiomyopathy	0.0334	0.532	CbGbCtD
Afatinib—ABCB1—Spironolactone—dilated cardiomyopathy	0.0294	0.468	CbGbCtD
Afatinib—DYRK1A—myocardium—dilated cardiomyopathy	0.00369	0.104	CbGeAlD
Afatinib—IRAK1—cardiac ventricle—dilated cardiomyopathy	0.00305	0.0859	CbGeAlD
Afatinib—PHKG2—heart—dilated cardiomyopathy	0.00297	0.0839	CbGeAlD
Afatinib—IRAK1—myocardium—dilated cardiomyopathy	0.00287	0.0808	CbGeAlD
Afatinib—ERBB4—heart—dilated cardiomyopathy	0.00267	0.0754	CbGeAlD
Afatinib—ERBB2—heart—dilated cardiomyopathy	0.00267	0.0754	CbGeAlD
Afatinib—DYRK1A—heart—dilated cardiomyopathy	0.00257	0.0726	CbGeAlD
Afatinib—ERBB4—cardiac atrium—dilated cardiomyopathy	0.00229	0.0645	CbGeAlD
Afatinib—EGFR—heart—dilated cardiomyopathy	0.00227	0.0639	CbGeAlD
Afatinib—Vandetanib—EGFR—dilated cardiomyopathy	0.00206	0.513	CrCbGaD
Afatinib—IRAK1—heart—dilated cardiomyopathy	0.002	0.0564	CbGeAlD
Afatinib—Gefitinib—EGFR—dilated cardiomyopathy	0.00195	0.487	CrCbGaD
Afatinib—LCK—heart—dilated cardiomyopathy	0.00195	0.055	CbGeAlD
Afatinib—ABL1—cardiac ventricle—dilated cardiomyopathy	0.00171	0.0481	CbGeAlD
Afatinib—ABL1—myocardium—dilated cardiomyopathy	0.00161	0.0453	CbGeAlD
Afatinib—Renal failure—Spironolactone—dilated cardiomyopathy	0.00137	0.0307	CcSEcCtD
Afatinib—Rhinorrhoea—Lisinopril—dilated cardiomyopathy	0.00125	0.0282	CcSEcCtD
Afatinib—Bladder pain—Furosemide—dilated cardiomyopathy	0.00122	0.0275	CcSEcCtD
Afatinib—ABL1—heart—dilated cardiomyopathy	0.00112	0.0316	CbGeAlD
Afatinib—Alopecia—Spironolactone—dilated cardiomyopathy	0.0011	0.0248	CcSEcCtD
Afatinib—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00105	0.0235	CcSEcCtD
Afatinib—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.000992	0.0223	CcSEcCtD
Afatinib—Cystitis—Lisinopril—dilated cardiomyopathy	0.00098	0.022	CcSEcCtD
Afatinib—ABL1—cardiac atrium—dilated cardiomyopathy	0.000959	0.027	CbGeAlD
Afatinib—Bladder pain—Lisinopril—dilated cardiomyopathy	0.000918	0.0206	CcSEcCtD
Afatinib—Dehydration—Furosemide—dilated cardiomyopathy	0.000914	0.0205	CcSEcCtD
Afatinib—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.000894	0.0201	CcSEcCtD
Afatinib—Renal impairment—Lisinopril—dilated cardiomyopathy	0.000774	0.0174	CcSEcCtD
Afatinib—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000766	0.0172	CcSEcCtD
Afatinib—Renal failure—Furosemide—dilated cardiomyopathy	0.000744	0.0167	CcSEcCtD
Afatinib—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.000716	0.0161	CcSEcCtD
Afatinib—ABCG2—heart—dilated cardiomyopathy	0.000707	0.0199	CbGeAlD
Afatinib—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000702	0.0158	CcSEcCtD
Afatinib—Dehydration—Lisinopril—dilated cardiomyopathy	0.000685	0.0154	CcSEcCtD
Afatinib—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000671	0.0151	CcSEcCtD
Afatinib—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000666	0.015	CcSEcCtD
Afatinib—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.000659	0.0148	CcSEcCtD
Afatinib—Eye disorder—Furosemide—dilated cardiomyopathy	0.000635	0.0143	CcSEcCtD
Afatinib—Pruritus—Spironolactone—dilated cardiomyopathy	0.000628	0.0141	CcSEcCtD
Afatinib—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000607	0.0136	CcSEcCtD
Afatinib—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.000592	0.0133	CcSEcCtD
Afatinib—Malnutrition—Furosemide—dilated cardiomyopathy	0.000592	0.0133	CcSEcCtD
Afatinib—Dizziness—Spironolactone—dilated cardiomyopathy	0.000587	0.0132	CcSEcCtD
Afatinib—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000579	0.013	CcSEcCtD
Afatinib—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000576	0.013	CcSEcCtD
Afatinib—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000571	0.0128	CcSEcCtD
Afatinib—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000569	0.0128	CcSEcCtD
Afatinib—Vomiting—Spironolactone—dilated cardiomyopathy	0.000564	0.0127	CcSEcCtD
Afatinib—Rash—Spironolactone—dilated cardiomyopathy	0.00056	0.0126	CcSEcCtD
Afatinib—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000559	0.0126	CcSEcCtD
Afatinib—Renal failure—Lisinopril—dilated cardiomyopathy	0.000558	0.0125	CcSEcCtD
Afatinib—Headache—Spironolactone—dilated cardiomyopathy	0.000556	0.0125	CcSEcCtD
Afatinib—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000552	0.0124	CcSEcCtD
Afatinib—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000537	0.0121	CcSEcCtD
Afatinib—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000536	0.012	CcSEcCtD
Afatinib—Nausea—Spironolactone—dilated cardiomyopathy	0.000527	0.0118	CcSEcCtD
Afatinib—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000504	0.0113	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.0005	0.0112	CcSEcCtD
Afatinib—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.0005	0.0112	CcSEcCtD
Afatinib—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000474	0.0106	CcSEcCtD
Afatinib—Skin disorder—Furosemide—dilated cardiomyopathy	0.000469	0.0105	CcSEcCtD
Afatinib—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00046	0.0103	CcSEcCtD
Afatinib—Alopecia—Lisinopril—dilated cardiomyopathy	0.000451	0.0101	CcSEcCtD
Afatinib—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000447	0.01	CcSEcCtD
Afatinib—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000444	0.00997	CcSEcCtD
Afatinib—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000435	0.00977	CcSEcCtD
Afatinib—Back pain—Lisinopril—dilated cardiomyopathy	0.000429	0.00965	CcSEcCtD
Afatinib—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000427	0.00959	CcSEcCtD
Afatinib—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00042	0.00943	CcSEcCtD
Afatinib—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000417	0.00937	CcSEcCtD
Afatinib—Fatigue—Furosemide—dilated cardiomyopathy	0.000416	0.00935	CcSEcCtD
Afatinib—Constipation—Furosemide—dilated cardiomyopathy	0.000413	0.00928	CcSEcCtD
Afatinib—Cough—Lisinopril—dilated cardiomyopathy	0.000387	0.0087	CcSEcCtD
Afatinib—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000382	0.00858	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000375	0.00843	CcSEcCtD
Afatinib—Infection—Lisinopril—dilated cardiomyopathy	0.00036	0.00809	CcSEcCtD
Afatinib—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000352	0.00791	CcSEcCtD
Afatinib—ABCB1—heart—dilated cardiomyopathy	0.000349	0.00983	CbGeAlD
Afatinib—Asthenia—Furosemide—dilated cardiomyopathy	0.000346	0.00778	CcSEcCtD
Afatinib—Pruritus—Furosemide—dilated cardiomyopathy	0.000342	0.00768	CcSEcCtD
Afatinib—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00033	0.00742	CcSEcCtD
Afatinib—Insomnia—Lisinopril—dilated cardiomyopathy	0.000328	0.00736	CcSEcCtD
Afatinib—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000323	0.00726	CcSEcCtD
Afatinib—Dizziness—Furosemide—dilated cardiomyopathy	0.000319	0.00717	CcSEcCtD
Afatinib—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000319	0.00717	CcSEcCtD
Afatinib—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000315	0.00708	CcSEcCtD
Afatinib—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000313	0.00703	CcSEcCtD
Afatinib—Fatigue—Lisinopril—dilated cardiomyopathy	0.000312	0.00702	CcSEcCtD
Afatinib—Constipation—Lisinopril—dilated cardiomyopathy	0.00031	0.00696	CcSEcCtD
Afatinib—Vomiting—Furosemide—dilated cardiomyopathy	0.000307	0.0069	CcSEcCtD
Afatinib—Rash—Furosemide—dilated cardiomyopathy	0.000304	0.00684	CcSEcCtD
Afatinib—Dermatitis—Furosemide—dilated cardiomyopathy	0.000304	0.00683	CcSEcCtD
Afatinib—Headache—Furosemide—dilated cardiomyopathy	0.000302	0.0068	CcSEcCtD
Afatinib—Nausea—Furosemide—dilated cardiomyopathy	0.000287	0.00644	CcSEcCtD
Afatinib—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000286	0.00644	CcSEcCtD
Afatinib—Asthenia—Lisinopril—dilated cardiomyopathy	0.00026	0.00584	CcSEcCtD
Afatinib—Pruritus—Lisinopril—dilated cardiomyopathy	0.000256	0.00576	CcSEcCtD
Afatinib—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000248	0.00557	CcSEcCtD
Afatinib—Dizziness—Lisinopril—dilated cardiomyopathy	0.00024	0.00538	CcSEcCtD
Afatinib—Vomiting—Lisinopril—dilated cardiomyopathy	0.00023	0.00518	CcSEcCtD
Afatinib—Rash—Lisinopril—dilated cardiomyopathy	0.000228	0.00513	CcSEcCtD
Afatinib—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000228	0.00513	CcSEcCtD
Afatinib—Headache—Lisinopril—dilated cardiomyopathy	0.000227	0.0051	CcSEcCtD
Afatinib—Nausea—Lisinopril—dilated cardiomyopathy	0.000215	0.00484	CcSEcCtD
Afatinib—LCK—Signaling by NGF—RAC1—dilated cardiomyopathy	6.66e-05	0.000465	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—SDHA—dilated cardiomyopathy	6.65e-05	0.000465	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	6.61e-05	0.000462	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—RAF1—dilated cardiomyopathy	6.58e-05	0.00046	CbGpPWpGaD
Afatinib—ERBB2—Signaling by NGF—EGFR—dilated cardiomyopathy	6.5e-05	0.000454	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—ITGB1—dilated cardiomyopathy	6.5e-05	0.000454	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—RAF1—dilated cardiomyopathy	6.49e-05	0.000453	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	6.49e-05	0.000453	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	6.49e-05	0.000453	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	6.43e-05	0.000449	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—RAF1—dilated cardiomyopathy	6.43e-05	0.000449	CbGpPWpGaD
Afatinib—ERBB4—Signaling by NGF—EGFR—dilated cardiomyopathy	6.41e-05	0.000448	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—ITGB1—dilated cardiomyopathy	6.38e-05	0.000446	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	6.37e-05	0.000445	CbGpPWpGaD
Afatinib—EGFR—Focal Adhesion—RAF1—dilated cardiomyopathy	6.36e-05	0.000444	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—RAF1—dilated cardiomyopathy	6.34e-05	0.000443	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	6.33e-05	0.000442	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—CD36—dilated cardiomyopathy	6.26e-05	0.000437	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	6.26e-05	0.000437	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	6.26e-05	0.000437	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—RAC1—dilated cardiomyopathy	6.26e-05	0.000437	CbGpPWpGaD
Afatinib—ABL1—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	6.13e-05	0.000428	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—RAF1—dilated cardiomyopathy	6.13e-05	0.000428	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PSEN2—dilated cardiomyopathy	6.11e-05	0.000427	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—TNF—dilated cardiomyopathy	6.08e-05	0.000425	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PSEN2—dilated cardiomyopathy	6.02e-05	0.00042	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	5.96e-05	0.000416	CbGpPWpGaD
Afatinib—ERBB2—Immune System—ITGB1—dilated cardiomyopathy	5.91e-05	0.000413	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—RAC1—dilated cardiomyopathy	5.9e-05	0.000412	CbGpPWpGaD
Afatinib—ERBB2—Axon guidance—EGFR—dilated cardiomyopathy	5.89e-05	0.000411	CbGpPWpGaD
Afatinib—PHKG2—Disease—RAF1—dilated cardiomyopathy	5.87e-05	0.00041	CbGpPWpGaD
Afatinib—ERBB4—Immune System—ITGB1—dilated cardiomyopathy	5.82e-05	0.000407	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	5.82e-05	0.000406	CbGpPWpGaD
Afatinib—ABL1—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	5.8e-05	0.000405	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	5.76e-05	0.000402	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	5.75e-05	0.000401	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—EGFR—dilated cardiomyopathy	5.68e-05	0.000396	CbGpPWpGaD
Afatinib—BLK—Immune System—ITGB1—dilated cardiomyopathy	5.6e-05	0.000391	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—ITGB1—dilated cardiomyopathy	5.56e-05	0.000388	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—CD36—dilated cardiomyopathy	5.55e-05	0.000387	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—CD36—dilated cardiomyopathy	5.44e-05	0.00038	CbGpPWpGaD
Afatinib—LCK—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	5.43e-05	0.000379	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.43e-05	0.000379	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.43e-05	0.000379	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—RAF1—dilated cardiomyopathy	5.41e-05	0.000378	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—TNF—dilated cardiomyopathy	5.41e-05	0.000378	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.34e-05	0.000373	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.34e-05	0.000373	CbGpPWpGaD
Afatinib—LCK—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	5.34e-05	0.000373	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—RAF1—dilated cardiomyopathy	5.33e-05	0.000372	CbGpPWpGaD
Afatinib—LCK—Hemostasis—ITGB1—dilated cardiomyopathy	5.25e-05	0.000367	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—RAC1—dilated cardiomyopathy	5.23e-05	0.000365	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—RAF1—dilated cardiomyopathy	5.2e-05	0.000363	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—RAC1—dilated cardiomyopathy	5.13e-05	0.000358	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—RAF1—dilated cardiomyopathy	5.12e-05	0.000357	CbGpPWpGaD
Afatinib—LCK—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	5.11e-05	0.000357	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	5.1e-05	0.000356	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	5.08e-05	0.000355	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.04e-05	0.000352	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD36—dilated cardiomyopathy	5.04e-05	0.000352	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB4—EGFR—dilated cardiomyopathy	5.02e-05	0.000351	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.97e-05	0.000347	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD36—dilated cardiomyopathy	4.97e-05	0.000347	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—RAF1—dilated cardiomyopathy	4.92e-05	0.000344	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	4.92e-05	0.000343	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CD36—dilated cardiomyopathy	4.9e-05	0.000342	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.88e-05	0.000341	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—RAF1—dilated cardiomyopathy	4.86e-05	0.000339	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	4.84e-05	0.000338	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	4.82e-05	0.000337	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.81e-05	0.000336	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—EGFR—dilated cardiomyopathy	4.8e-05	0.000335	CbGpPWpGaD
Afatinib—BLK—Immune System—CD36—dilated cardiomyopathy	4.78e-05	0.000334	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR—EGFR—dilated cardiomyopathy	4.78e-05	0.000334	CbGpPWpGaD
Afatinib—ERBB2—Immune System—RAC1—dilated cardiomyopathy	4.75e-05	0.000332	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—EGFR—dilated cardiomyopathy	4.75e-05	0.000332	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—CD36—dilated cardiomyopathy	4.74e-05	0.000331	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—EGFR—dilated cardiomyopathy	4.73e-05	0.00033	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—ITGB1—dilated cardiomyopathy	4.71e-05	0.000329	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—EGFR—dilated cardiomyopathy	4.7e-05	0.000328	CbGpPWpGaD
Afatinib—ERBB4—Immune System—RAC1—dilated cardiomyopathy	4.68e-05	0.000327	CbGpPWpGaD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	4.66e-05	0.000326	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—RAC1—dilated cardiomyopathy	4.62e-05	0.000322	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—RAF1—dilated cardiomyopathy	4.59e-05	0.00032	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	4.58e-05	0.00032	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—ITGB1—dilated cardiomyopathy	4.54e-05	0.000317	CbGpPWpGaD
Afatinib—BLK—Immune System—RAC1—dilated cardiomyopathy	4.5e-05	0.000315	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—RAF1—dilated cardiomyopathy	4.49e-05	0.000314	CbGpPWpGaD
Afatinib—LCK—Hemostasis—CD36—dilated cardiomyopathy	4.48e-05	0.000313	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—RAC1—dilated cardiomyopathy	4.47e-05	0.000312	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—EGFR—dilated cardiomyopathy	4.45e-05	0.000311	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	4.45e-05	0.000311	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	4.45e-05	0.000311	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AGTR2—dilated cardiomyopathy	4.44e-05	0.00031	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCL2—dilated cardiomyopathy	4.44e-05	0.00031	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—RAF1—dilated cardiomyopathy	4.42e-05	0.000309	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.42e-05	0.000309	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—EGFR—dilated cardiomyopathy	4.41e-05	0.000308	CbGpPWpGaD
Afatinib—ERBB2—Disease—RAC1—dilated cardiomyopathy	4.39e-05	0.000306	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	4.37e-05	0.000305	CbGpPWpGaD
Afatinib—EGFR—Disease—NPPA—dilated cardiomyopathy	4.36e-05	0.000304	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—EGFR—dilated cardiomyopathy	4.35e-05	0.000304	CbGpPWpGaD
Afatinib—ERBB4—Disease—RAC1—dilated cardiomyopathy	4.32e-05	0.000302	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ITGB1—dilated cardiomyopathy	4.27e-05	0.000299	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	4.23e-05	0.000296	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	4.23e-05	0.000295	CbGpPWpGaD
Afatinib—LCK—Hemostasis—RAC1—dilated cardiomyopathy	4.22e-05	0.000295	CbGpPWpGaD
Afatinib—EGFR—Disease—PSEN2—dilated cardiomyopathy	4.22e-05	0.000295	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—EGFR—dilated cardiomyopathy	4.2e-05	0.000293	CbGpPWpGaD
Afatinib—LCK—Disease—NPPA—dilated cardiomyopathy	4.2e-05	0.000293	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CD36—dilated cardiomyopathy	4.19e-05	0.000292	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.17e-05	0.000291	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—RAF1—dilated cardiomyopathy	4.15e-05	0.00029	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	4.14e-05	0.000289	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCR3—dilated cardiomyopathy	4.13e-05	0.000288	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—EGFR—dilated cardiomyopathy	4.12e-05	0.000288	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.11e-05	0.000287	CbGpPWpGaD
Afatinib—LCK—Disease—PSEN2—dilated cardiomyopathy	4.07e-05	0.000284	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CD36—dilated cardiomyopathy	4.03e-05	0.000282	CbGpPWpGaD
Afatinib—PHKG2—Disease—EGFR—dilated cardiomyopathy	4.02e-05	0.000281	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD36—dilated cardiomyopathy	4.02e-05	0.000281	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—TNF—dilated cardiomyopathy	4e-05	0.000279	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—ADRB1—dilated cardiomyopathy	4e-05	0.000279	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	3.98e-05	0.000278	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.96e-05	0.000276	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—RAC1—dilated cardiomyopathy	3.94e-05	0.000276	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	3.94e-05	0.000275	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.92e-05	0.000274	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.92e-05	0.000274	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—RAF1—dilated cardiomyopathy	3.91e-05	0.000273	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.9e-05	0.000272	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD36—dilated cardiomyopathy	3.87e-05	0.000271	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—RAC1—dilated cardiomyopathy	3.8e-05	0.000265	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—RAC1—dilated cardiomyopathy	3.79e-05	0.000265	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—EGFR—dilated cardiomyopathy	3.71e-05	0.000259	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—EGFR—dilated cardiomyopathy	3.65e-05	0.000255	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—RAC1—dilated cardiomyopathy	3.65e-05	0.000255	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.65e-05	0.000255	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD36—dilated cardiomyopathy	3.65e-05	0.000255	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	3.6e-05	0.000251	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—EGFR—dilated cardiomyopathy	3.56e-05	0.000249	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.53e-05	0.000247	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—EGFR—dilated cardiomyopathy	3.51e-05	0.000245	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—RAF1—dilated cardiomyopathy	3.47e-05	0.000242	CbGpPWpGaD
Afatinib—IRAK1—Immune System—RAC1—dilated cardiomyopathy	3.44e-05	0.00024	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AGTR1—dilated cardiomyopathy	3.41e-05	0.000238	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.4e-05	0.000238	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—RAF1—dilated cardiomyopathy	3.4e-05	0.000237	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—EGFR—dilated cardiomyopathy	3.38e-05	0.000236	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.35e-05	0.000234	CbGpPWpGaD
Afatinib—ABL1—Immune System—ITGB1—dilated cardiomyopathy	3.34e-05	0.000234	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—EGFR—dilated cardiomyopathy	3.33e-05	0.000233	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—ADRB2—dilated cardiomyopathy	3.24e-05	0.000226	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	3.2e-05	0.000223	CbGpPWpGaD
Afatinib—ERBB2—Immune System—RAF1—dilated cardiomyopathy	3.15e-05	0.00022	CbGpPWpGaD
Afatinib—ERBB4—Immune System—RAF1—dilated cardiomyopathy	3.1e-05	0.000217	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—RAC1—dilated cardiomyopathy	3.07e-05	0.000215	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—RAF1—dilated cardiomyopathy	3.06e-05	0.000214	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—EGFR—dilated cardiomyopathy	3.03e-05	0.000212	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—RAC1—dilated cardiomyopathy	3.03e-05	0.000211	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.02e-05	0.000211	CbGpPWpGaD
Afatinib—BLK—Immune System—RAF1—dilated cardiomyopathy	2.99e-05	0.000209	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—RAF1—dilated cardiomyopathy	2.96e-05	0.000207	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.95e-05	0.000206	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AGT—dilated cardiomyopathy	2.94e-05	0.000205	CbGpPWpGaD
Afatinib—ERBB2—Disease—RAF1—dilated cardiomyopathy	2.91e-05	0.000203	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AGT—dilated cardiomyopathy	2.89e-05	0.000202	CbGpPWpGaD
Afatinib—ERBB4—Disease—RAF1—dilated cardiomyopathy	2.87e-05	0.0002	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.86e-05	0.0002	CbGpPWpGaD
Afatinib—EGFR—Immune System—ITGB1—dilated cardiomyopathy	2.86e-05	0.0002	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD36—dilated cardiomyopathy	2.85e-05	0.000199	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.85e-05	0.000199	CbGpPWpGaD
Afatinib—LCK—Hemostasis—RAF1—dilated cardiomyopathy	2.8e-05	0.000196	CbGpPWpGaD
Afatinib—LCK—Immune System—ITGB1—dilated cardiomyopathy	2.75e-05	0.000192	CbGpPWpGaD
Afatinib—ABL1—Immune System—RAC1—dilated cardiomyopathy	2.69e-05	0.000188	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—EGFR—dilated cardiomyopathy	2.68e-05	0.000187	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.62e-05	0.000183	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.62e-05	0.000183	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—RAF1—dilated cardiomyopathy	2.62e-05	0.000183	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.53e-05	0.000177	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.53e-05	0.000177	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—RAF1—dilated cardiomyopathy	2.52e-05	0.000176	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—RAC1—dilated cardiomyopathy	2.51e-05	0.000176	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—RAF1—dilated cardiomyopathy	2.51e-05	0.000175	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.46e-05	0.000172	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.44e-05	0.00017	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD36—dilated cardiomyopathy	2.44e-05	0.00017	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—RAF1—dilated cardiomyopathy	2.42e-05	0.000169	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AGT—dilated cardiomyopathy	2.4e-05	0.000168	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—EGFR—dilated cardiomyopathy	2.38e-05	0.000166	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.36e-05	0.000165	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.35e-05	0.000164	CbGpPWpGaD
Afatinib—LCK—Immune System—CD36—dilated cardiomyopathy	2.35e-05	0.000164	CbGpPWpGaD
Afatinib—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.35e-05	0.000164	CbGpPWpGaD
Afatinib—EGFR—Immune System—RAC1—dilated cardiomyopathy	2.3e-05	0.00016	CbGpPWpGaD
Afatinib—IRAK1—Immune System—RAF1—dilated cardiomyopathy	2.28e-05	0.000159	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.28e-05	0.000159	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TNF—dilated cardiomyopathy	2.26e-05	0.000158	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.22e-05	0.000155	CbGpPWpGaD
Afatinib—LCK—Immune System—RAC1—dilated cardiomyopathy	2.21e-05	0.000155	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	2.19e-05	0.000153	CbGpPWpGaD
Afatinib—ERBB2—Immune System—EGFR—dilated cardiomyopathy	2.16e-05	0.000151	CbGpPWpGaD
Afatinib—ERBB4—Immune System—EGFR—dilated cardiomyopathy	2.13e-05	0.000149	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AGT—dilated cardiomyopathy	2.12e-05	0.000148	CbGpPWpGaD
Afatinib—EGFR—Disease—RAC1—dilated cardiomyopathy	2.12e-05	0.000148	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—EGFR—dilated cardiomyopathy	2.1e-05	0.000147	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	2.09e-05	0.000146	CbGpPWpGaD
Afatinib—BLK—Immune System—EGFR—dilated cardiomyopathy	2.05e-05	0.000143	CbGpPWpGaD
Afatinib—LCK—Disease—RAC1—dilated cardiomyopathy	2.04e-05	0.000143	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—RAF1—dilated cardiomyopathy	2.04e-05	0.000142	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.02e-05	0.000141	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—RAF1—dilated cardiomyopathy	2.01e-05	0.00014	CbGpPWpGaD
Afatinib—ERBB2—Disease—EGFR—dilated cardiomyopathy	2e-05	0.000139	CbGpPWpGaD
Afatinib—ERBB4—Disease—EGFR—dilated cardiomyopathy	1.97e-05	0.000137	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.94e-05	0.000136	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—dilated cardiomyopathy	1.93e-05	0.000135	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.91e-05	0.000134	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.84e-05	0.000129	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	1.81e-05	0.000126	CbGpPWpGaD
Afatinib—ABL1—Immune System—RAF1—dilated cardiomyopathy	1.78e-05	0.000125	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CD36—dilated cardiomyopathy	1.76e-05	0.000123	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EGFR—dilated cardiomyopathy	1.73e-05	0.000121	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.67e-05	0.000116	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—dilated cardiomyopathy	1.66e-05	0.000116	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.64e-05	0.000115	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AGT—dilated cardiomyopathy	1.58e-05	0.000111	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.58e-05	0.000111	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—dilated cardiomyopathy	1.56e-05	0.000109	CbGpPWpGaD
Afatinib—EGFR—Immune System—RAF1—dilated cardiomyopathy	1.52e-05	0.000106	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RAC1—dilated cardiomyopathy	1.49e-05	0.000104	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.47e-05	0.000103	CbGpPWpGaD
Afatinib—LCK—Immune System—RAF1—dilated cardiomyopathy	1.47e-05	0.000103	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RAC1—dilated cardiomyopathy	1.43e-05	0.0001	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AGT—dilated cardiomyopathy	1.42e-05	9.91e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—RAF1—dilated cardiomyopathy	1.41e-05	9.82e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—dilated cardiomyopathy	1.4e-05	9.76e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—dilated cardiomyopathy	1.38e-05	9.61e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AGT—dilated cardiomyopathy	1.37e-05	9.55e-05	CbGpPWpGaD
Afatinib—LCK—Disease—RAF1—dilated cardiomyopathy	1.36e-05	9.47e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.27e-05	8.87e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—dilated cardiomyopathy	1.22e-05	8.54e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.01e-05	7.05e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—dilated cardiomyopathy	1.01e-05	7.03e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RAF1—dilated cardiomyopathy	9.85e-06	6.88e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	9.77e-06	6.82e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CD36—dilated cardiomyopathy	9.51e-06	6.65e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RAF1—dilated cardiomyopathy	9.49e-06	6.63e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—dilated cardiomyopathy	9.29e-06	6.49e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AGT—dilated cardiomyopathy	8.57e-06	5.98e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—dilated cardiomyopathy	6.51e-06	4.55e-05	CbGpPWpGaD
